Logo

Novavax Receives the US FDA's Fast Track Designation for NVX-CoV2373 to Treat COVID-19

Share this

Novavax Receives the US FDA's Fast Track Designation for NVX-CoV2373 to Treat COVID-19

Shots:

  • The US FDA has granted FT designation to NVX-CoV2373 which is currently in late-phase clinical development. Novavax expects to initiate pivotal P-III study in the US & Mexico by the end of Nov’2020
  • The company’s ongoing P-lll trial in the UK to evaluate the efficacy- safety- and immunogenicity of NVX-CoV2373 is expected to be fully enrolled by the end of Nov. Depending on the overall COVID-19 attack rate- interim data in the UK trial is expected in Q1’21
  • NVXCoV2373 is a stable- prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant

­ Ref: Novavax | Image: Newsroom Keck Medicine of USC

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions